标题/作者	年份
Tumor necrosis factor inhibitors for inflammatory bowel disease OH Nielsen, MA Ainsworth New England Journal of Medicine 369 (8), 754-762	2013
Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis B Barberio, M Zamani, CJ Black, EV Savarino, AC Ford The Lancet Gastroenterology & Hepatology 6 (5), 359-370	2021
Paradoxical gastrointestinal effects of interleukin-17 blockers M Fauny, D Moulin, F d'Amico, P Netter, N Petitpain, D Arnone, ... Annals of the rheumatic diseases 79 (9), 1132-1138	2020
Calprotectin: from biomarker to biological function A Jukic, L Bakiri, EF Wagner, H Tilg, TE Adolph Gut 70 (10), 1978-1988	2021
Serum biomarkers for inflammatory bowel disease P Chen, G Zhou, J Lin, L Li, Z Zeng, M Chen, S Zhang Frontiers in Medicine 7, 123	2020
Newer biologic and small-molecule therapies for inflammatory bowel disease DC Baumgart, C Le Berre New England Journal of Medicine 385 (14), 1302-1315	2021
Pathophysiology of Crohn’s disease inflammation and recurrence L Petagna, A Antonelli, C Ganini, V Bellato, M Campanelli, A Divizia, ... Biology direct 15 (1), 1-10	2020
Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease S Schreiber, S Ben-Horin, J Leszczyszyn, R Dudkowiak, A Lahat, ... Gastroenterology 160 (7), 2340-2353	2021
The role of diet in the pathogenesis and management of inflammatory bowel disease: a review G Wark, D Samocha-Bonet, S Ghaly, M Danta Nutrients 13 (1), 135	2020
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial H Yanai, A Levine, A Hirsch, RS Boneh, U Kopylov, HB Eran, NA Cohen, ... The Lancet Gastroenterology & Hepatology 7 (1), 49-59	2022
Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial SW Syversen, KK Jørgensen, GL Goll, MK Brun, Ø Sandanger, ... Jama 326 (23), 2375-2384	2021
Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease A Chupin, V Perduca, A Meyer, C Bellanger, F Carbonnel, C Dong Alimentary Pharmacology & Therapeutics 52 (8), 1289-1297	2020
Location is important: differentiation between ileal and colonic Crohn’s disease R Atreya, B Siegmund Nature Reviews Gastroenterology & Hepatology 18 (8), 544-558	2021
Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект) ВТ Ивашкин, ЮА Шелыгин, ДИ Абдулганиева, РА Абдулхаков, ... Колопроктология 19 (2), 8-38	2020
Treatment algorithms for Crohn’s disease MC Sulz, E Burri, P Michetti, G Rogler, L Peyrin-Biroulet, F Seibold Digestion 101 (Suppl. 1), 43-57	2020
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn’s disease G Pellino, DS Keller, GM Sampietro, I Angriman, M Carvello, V Celentano, ... Techniques in coloproctology 24, 421-448	2020
No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis C Yzet, M Diouf, S Singh, F Brazier, J Turpin, E Nguyen-Khac, J Meynier, ... Clinical Gastroenterology and Hepatology 19 (4), 668-679. e8	2021
local tumor necrosis factor-α inhibition in inflammatory bowel disease B Gareb, AT Otten, HW Frijlink, G Dijkstra, JGW Kosterink Pharmaceutics 12 (6), 539	2020
Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease G Privitera, S Onali, D Pugliese, S Renna, E Savarino, A Viola, ... Journal of Crohn's and Colitis 15 (2), 335-339	2021
Effectiveness and safety of ustekinumab intensification at 90 mg every 4 weeks in Crohn’s disease: a multicentre study M Fumery, L Peyrin-Biroulet, S Nancey, R Altwegg, C Gilletta, P Veyrard, ... Journal of Crohn's and Colitis 15 (2), 222-227	2021

1 - 20

计算机程序会自动估算并确定日期和引用次数。